NASDAQ: CRONCronos Group Inc Stock
$2.47+0.11 (+4.66%)
Updated Apr 23, 2024
CRON Price
$2.47
Fair Value Price
N/A
Market Cap
$941.81M
52 Week Low
$1.64
52 Week High
$2.99
P/E
-13x
P/B
0.86x
P/S
9.13x
PEG
N/A
Dividend Yield
N/A
Revenue
$87.24M
Earnings
-$73.96M
Gross Margin
13.7%
Operating Margin
-147.21%
Profit Margin
-84.8%
Debt to Equity
0.04
Operating Cash Flow
-$43M
Beta
1.26
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CRON Overview
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. It also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CRON scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRON is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CRON is good value based on its book value relative to its share price (0.86x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.07x)
P/B vs Industry Valuation
CRON is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CRON due diligence checks available for Premium users.
Be the first to know about important CRON news, forecast changes, insider trades & much more!
CRON News
Valuation
CRON fair value
Fair Value of CRON stock based on Discounted Cash Flow (DCF)
Price
$2.47
Fair Value
$3.10
Undervalued by
20.43%
CRON is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CRON price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-13x
Industry
46.85x
Market
41.92x
CRON price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.86x
Industry
2.07x
CRON is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRON's financial health
Profit margin
Revenue
$23.9M
Net Income
-$44.8M
Profit Margin
-187.3%
CRON's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CRON's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.1B
Liabilities
$44.0M
Debt to equity
0.04
CRON's short-term assets ($933.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRON's short-term assets ($933.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRON's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CRON's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$16.8M
Investing
$81.9M
Financing
N/A
CRON's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CRON vs Pharmaceutical Stocks
Cronos Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.